- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT04754854
Verenkierron vähentäminen veno-venous ECMO:ssa
Verenkierron vähentäminen laskimo-laskimo-ECMO:ssa ultraäänilaimennusmittauksilla (ECMO Circulation Study)
Blood which recirculates through the circuit of a veno-venous Extracorporeal Membrane Oxygenation (V-V ECMO) does not contribute to the systemic oxygenation of a patient on V-V ECMO and is called the recirculation fraction (Rf). Theoretically, the optimization of ECMO blood flow is possible using Rf measurements.
A prospective, observational study will be performed measuring the Rf of total ECMO blood flow in patients with acute respiratory distress syndrome (ARDS) on V-V ECMO with an ultrasound dilution technique.
ECMO blood flow will be optimized by reducing ECMO blood flow in accordance with the measured Rf as long as systemic oxygenation is not compromised.
Tutkimuksen yleiskatsaus
Tila
Yksityiskohtainen kuvaus
Based on data from the 'Blood Recirculation and vvECMO' trial (ClinicalTrials.gov ID: NCT03200314) (i.e. an expected frequency of successful blood flow reduction of 66.7%), using a one-sample Chi square test, a two-sided type-1 error of 5%, a power of 80%, a total of 68 patients is needed to show that the proportion of patients with a secure ECMO blood flow reduction is greater than 50%. Presumably, 136 Patients have to be included into the trial to study 68 patients with a relevant Rf since not all patients on V-V ECMO suffer from a high Rf.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Yhteystiedot ja paikat
Opiskelupaikat
-
-
State of Berlin
-
Berlin, State of Berlin, Saksa, 13353
- Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
Inclusion Criteria:
- patients aged 18 years or older
- ARDS
- veno-venous ECMO
Exclusion Criteria:
- age < 18 years
- hemodynamic instability during measurement of recirculation
- pregnancy
- inability to obtain patient's consent or consent of legal guardian
Kuvaus
Patients aged 18 years or older requiring veno-venous ECMO for treatment of refractory hypoxemia in ARDS.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: COHORT
- Aikanäkymät: PROSPECTIVE
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Successful ECMO blood flow reduction
Aikaikkuna: Once within the first week after initiation of ECMO therapy
|
Number of patients with a relevant recirculation fraction and successful ECMO blood flow reduction |
Once within the first week after initiation of ECMO therapy
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Recirculation fraction
Aikaikkuna: Once within the first week after initiation of ECMO therapy
|
Fraction of blood recirculating through the ECMO circuit |
Once within the first week after initiation of ECMO therapy
|
|
Arterial blood oxygen content
Aikaikkuna: Once within the first week after initiation of ECMO therapy
|
Arterial blood oxygen content before vs. after reduction of ECMO blood flow |
Once within the first week after initiation of ECMO therapy
|
|
Extracorporeal blood Flow
Aikaikkuna: Once within the first week after initiation of ECMO therapy
|
ECMO Blood Flow before vs. after reduction of ECMO blood flow |
Once within the first week after initiation of ECMO therapy
|
|
Extracorporeal gas flow
Aikaikkuna: Once within the first week after initiation of ECMO therapy
|
ECMO Sweep Gas flow |
Once within the first week after initiation of ECMO therapy
|
|
Length of ECMO therapy
Aikaikkuna: Daily until the end of ECMO therapy (approximately 14 days)
|
Days on ECMO |
Daily until the end of ECMO therapy (approximately 14 days)
|
|
Cannula position and distance
Aikaikkuna: Once within the first week after initiation of ECMO therapy
|
The distance between the tip of drainage and return cannula will be measured in the existing medical imaging (e.g. CT scans) |
Once within the first week after initiation of ECMO therapy
|
|
Right heart dysfunction
Aikaikkuna: Once within the first week after initiation of ECMO therapy
|
Existing echocardiography will be evaluated for possible right heart dysfunction |
Once within the first week after initiation of ECMO therapy
|
|
Length of mechanical ventilation
Aikaikkuna: Entire duration of the ICU stay (approximately 28 days)
|
Length of mechanical ventilation |
Entire duration of the ICU stay (approximately 28 days)
|
|
Complications of ECMO therapy
Aikaikkuna: Length of ECMO therapy (approximately 14 days)
|
Incidence of cannula or system changes (i.e. due to circuit clotting), complications attributed to ECMO therapy like bleeding complications from the cannulation site, transfusion requirements, hemolysis |
Length of ECMO therapy (approximately 14 days)
|
|
ICU mortality
Aikaikkuna: Entire duration of the ICU stay (approximately 28 days)
|
ICU mortality |
Entire duration of the ICU stay (approximately 28 days)
|
|
ICU length of stay
Aikaikkuna: Entire duration of the ICU stay (approximately 28 days)
|
ICU length of stay |
Entire duration of the ICU stay (approximately 28 days)
|
|
Incidence of ICU-acquired organ dysfunctions and complications
Aikaikkuna: Entire duration of the ICU stay (approximately 28 days)
|
Cerebral-, cardiovascular-, cardiac- pulmonary-, gastrointestinal- and renal dysfunctions, ICU-acquired infections |
Entire duration of the ICU stay (approximately 28 days)
|
|
ECMO blood flow over time
Aikaikkuna: Daily until the end of ECMO therapy (approximately 14 days)
|
ECMO blood and sweep gas flow over time |
Daily until the end of ECMO therapy (approximately 14 days)
|
|
ECMO sweep gas flow over time
Aikaikkuna: Daily until the end of ECMO therapy (approximately 14 days)
|
ECMO sweep gas flow over time |
Daily until the end of ECMO therapy (approximately 14 days)
|
|
Mobility at ICU discharge
Aikaikkuna: Discharge from the ICU (approximately 28 days)
|
Level of mobility the patient has reached at ICU discharge (recumbent, sitting, standing, walking with help, walking independently) |
Discharge from the ICU (approximately 28 days)
|
|
Weaning level at ICU discharge
Aikaikkuna: Discharge from the ICU (approximately 28 days)
|
Level of weaning reached at ICU discharge |
Discharge from the ICU (approximately 28 days)
|
|
Status of mechanical ventilation at ICU discharge
Aikaikkuna: Discharge from the ICU (approximately 28 days)
|
Status of mechanical ventilation at ICU discharge including all relevant settings and parameters |
Discharge from the ICU (approximately 28 days)
|
|
Level of organ dysfunction at ICU discharge
Aikaikkuna: Discharge from the ICU (approximately 28 days)
|
Sepsis-related Organ Failure Assessment Score at ICU discharge |
Discharge from the ICU (approximately 28 days)
|
|
Level of consciousness at ICU discharge
Aikaikkuna: Discharge from the ICU (approximately 28 days)
|
Glasgow Coma Scale at ICU discharge |
Discharge from the ICU (approximately 28 days)
|
|
Level of disease severity
Aikaikkuna: Discharge from the ICU (approximately 28 days)
|
Acute Physiology And Chronic Health Evaluation at ICU discharge |
Discharge from the ICU (approximately 28 days)
|
|
Hospital acquired infections related to ECMO therapy
Aikaikkuna: Entire duration of ECMO therapy
|
Infection/colonisation of the ECMO circuit |
Entire duration of ECMO therapy
|
|
Bleeding and thrombembolic complications of ECMO therapy
Aikaikkuna: Entire duration of ECMO therapy
|
Bleeding complications, thrombembolic events, overall use of blood products and coagulation factors, electron microscopic evaluation of selected membranes after change or weaning of the ECMO circuit |
Entire duration of ECMO therapy
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Martin Russ, Dr. med., Charite University Hospital Berlin
- Päätutkija: Philipp A Pickerodt, Dr. med., Charite University Hospital Berlin
- Päätutkija: Vladimir Skrypnikov, Dr. med., Charite University Hospital Berlin
- Päätutkija: Steffen Weber-Carstens, Prof. Dr. med., Charite University Hospital Berlin
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- EA115620
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .